Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

Inclusion criteria

• For the patients:

• Genetically confirmed diagnosis of DMD, FSHD, DM1, CMT or FKRP mutations orconfirmed CNM based on muscle biopsy.

• FSHD, DM1, CMT and CNM patients should be ambulant or in transition.

• DM1 and CMT patients should present sensori-motor signs on physicalexamination.

• Under the age of 20 years for patients with DMD, CNM or between the ages of 5and 80 years for patients with FSHD, CMT and DM1.

• More than 2 years old for patients with FKRP mutations

• Non-ambulant DMD patients must be able to remain seated in an arm- or awheelchair for at least one hour.

• Patients with DMD treated with corticosteroids for at least 6 months orinitiated corticosteroid at V0 (except for patients under 4).

• Signed informed consent form by patient himself or, in case of minor patients,signed informed consent form by patient's parents or legal guardians.

• For the control subjects:

• Ambulant boys and girls under 20 years old

• Signed informed consent form by patient him/herself or, in case of minorpatients, signed informed consent form by patient's parents or legal guardians.

Exclusion Criteria:

• For the patients:

• Patients with extreme cognitive disorders that limit their understanding of theexercises to be performed.

• Patients who have undergone a surgical procedure or who have experienced recenttrauma (within fewer than 6 months) affecting the upper or lower limbs (forambulant patients).

• A concomitant chronic or acute neurological, endocrine, infectious, allergic,or inflammatory pathology within the 3-week period immediately prior toinclusion.

• Patients who are participating in an interventional clinical trial.

• DMD patients in transition who are not on corticosteroids.

• For the control subjects:

• Patients who have undergone a surgical procedure or who have experienced recenttrauma (within fewer than 6 months) affecting the upper or lower limbs.

• Elite athletes (at the national level).

• A chronic or acute muscular, neurological, infectious, or inflammatorypathology within the 3-week period immediately prior to inclusion.

• An orthopedic, neuromuscular, or neurological pathology that affects thequality of the subject's walking gait.